Geode Capital Management LLC Has $73.19 Million Holdings in Vera Therapeutics, Inc. $VERA

Geode Capital Management LLC lifted its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 9.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,444,925 shares of the company’s stock after buying an additional 123,350 shares during the quarter. Geode Capital Management LLC owned about 2.26% of Vera Therapeutics worth $73,185,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Deerfield Management Company L.P. boosted its stake in Vera Therapeutics by 8.8% during the third quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock worth $105,812,000 after acquiring an additional 293,040 shares in the last quarter. Vanguard Group Inc. boosted its stake in Vera Therapeutics by 11.9% during the fourth quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock worth $180,805,000 after acquiring an additional 379,748 shares in the last quarter. Vestal Point Capital LP boosted its stake in Vera Therapeutics by 24.0% during the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock worth $73,036,000 after acquiring an additional 600,000 shares in the last quarter. Integral Health Asset Management LLC boosted its stake in Vera Therapeutics by 47.8% during the third quarter. Integral Health Asset Management LLC now owns 1,700,000 shares of the company’s stock worth $49,402,000 after acquiring an additional 550,000 shares in the last quarter. Finally, Schroder Investment Management Group boosted its stake in Vera Therapeutics by 82.4% during the third quarter. Schroder Investment Management Group now owns 679,992 shares of the company’s stock worth $19,652,000 after acquiring an additional 307,243 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Jefferies Financial Group reissued a “buy” rating and set a $60.00 target price on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. TD Cowen reissued a “buy” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. William Blair reissued an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th. Finally, Evercore set a $91.00 target price on shares of Vera Therapeutics in a research note on Friday, May 15th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $78.00.

Vera Therapeutics Stock Down 1.7%

Vera Therapeutics stock opened at $31.75 on Tuesday. Vera Therapeutics, Inc. has a 1-year low of $19.07 and a 1-year high of $56.05. The firm has a market capitalization of $2.28 billion, a price-to-earnings ratio of -5.73 and a beta of 0.93. The firm’s fifty day moving average price is $37.54 and its two-hundred day moving average price is $41.35. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter in the previous year, the company earned ($0.81) EPS. On average, equities research analysts predict that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current fiscal year.

Insider Activity at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 18,500 shares of the stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $36.74, for a total value of $679,690.00. Following the completion of the sale, the chief executive officer owned 216,744 shares in the company, valued at $7,963,174.56. This represents a 7.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is currently owned by corporate insiders.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.